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Introduction {#jgh14289-sec-0005}
============

Esophageal cancer is the eighth most common form of cancer in incidence and the sixth common cause of death from cancer worldwide, with 456 000 new cases and 400 100 deaths according to the GLOBOCAN 2012.[1](#jgh14289-bib-0001){ref-type="ref"} Its worldwide incidence is believed to be increasing.[2](#jgh14289-bib-0002){ref-type="ref"} Age‐standardized incidence and mortality rates of esophageal cancer are the highest in Eastern Asia as well as Southern and Eastern Africa, and around 80% of the cases worldwide occur in less developed regions.[1](#jgh14289-bib-0001){ref-type="ref"} There are two different histological types, namely, squamous cell carcinoma and adenocarcinoma, although there is only a marginal difference in their treatment strategy. Squamous esophageal cancer is one of most aggressive cancer, and its incidence and mortality have been decreasing in Asian countries including China and Japan.[3](#jgh14289-bib-0003){ref-type="ref"}, [4](#jgh14289-bib-0004){ref-type="ref"}, [5](#jgh14289-bib-0005){ref-type="ref"}, [6](#jgh14289-bib-0006){ref-type="ref"} However, the incidence of esophageal adenocarcinoma, which is related with gastro‐esophageal reflux disease (GERD), obesity, smoking, and dietary factors, continues to increase, especially in the USA[7](#jgh14289-bib-0007){ref-type="ref"}, [8](#jgh14289-bib-0008){ref-type="ref"} and Canada.[9](#jgh14289-bib-0009){ref-type="ref"}

Over the past several decades, correlated with the economic development, the dietary patterns have westernized, increasing the rates of obesity, and the prevalence of *Helicobacter pylori* infection has decreased during a relatively short period of time in Korea. These changes might be attributable to decrease in the incidence of squamous esophageal carcinoma but increase in the incidence of esophageal adenocarcinoma. On the other hand, gastric adenocarcinoma is the second most common cancer and the third leading cause of cancer deaths in Korea.[10](#jgh14289-bib-0010){ref-type="ref"} A population‐based screening program for gastric cancer was implemented in 2002 as a part of the National Cancer Screening Program (NCSP) for persons aged 40 years and older by using upper gastrointestinal series or endoscopy biennially.[11](#jgh14289-bib-0011){ref-type="ref"} This organized screening program may help in the detection of esophageal carcinoma, especially in early stages.

In the present study, we aimed to describe the trends of incidence and survival rates of esophageal cancer during different time periods according to sex, age groups, and histological subtypes from a population‐based cancer registry in Korea.

Methods {#jgh14289-sec-0006}
=======

Data sources {#jgh14289-sec-0007}
------------

The Korea Central Cancer Registry (KCCR), a nationwide, hospital‐based cancer registry, was initiated by the Ministry of Health and Welfare, Korea, in 1980.[12](#jgh14289-bib-0012){ref-type="ref"} Since 1999, the KCCR expanded cancer registration to cover the entire Korean population under the Population‐Based Regional Cancer Registry program.[12](#jgh14289-bib-0012){ref-type="ref"} In this database, the completeness of cancer incidence was 97.7% in 2012, as determined by the Ajuki method.[13](#jgh14289-bib-0013){ref-type="ref"} Quality indices for esophageal cancer such as the proportion of death certification, mortality/incidence ratio, and the proportion of microscopic verification are presented in Table [S1](#jgh14289-supitem-0001){ref-type="supplementary-material"}. Informed consent was not required because of the anonymity of the records in the data registry.

Esophageal cancer incidence {#jgh14289-sec-0008}
---------------------------

Age‐specific (5‐year intervals) and sex‐specific incidence rates and the number of cases for esophageal cancer patients between 1999 and 2013 were obtained from the Korea National Cancer Incidence Database. Histological subtypes of esophageal cancer were classified as follows: squamous cell carcinoma (International Classification of Diseases for Oncology third edition morphological codes 8050--8078, 8083--8084), adenocarcinoma (8140--8141, 8143--8145, 8190--8231, 8260--8263, 8310, 8401, 8480--8490, 8550--8551, 8570--8574, 8576), other specified (unspecified carcinoma: 8010--8035; sarcoma: 8800--8811, 8830, 8840--8921, 8990--8991, 9040--9044, 9120--9133, 9150, 9540--9581), and unspecified (8000--8005). Anatomical subsites were classified as follows: upper third of the esophagus (International Classification of Diseases 10 code C15.0, C15.3), middle third of the esophagus (C15.4), lower third of the esophagus (C15.5), thoracic (15.1), abdominal (C15.2), and overlapping lesion or not otherwise specified (C15.8--15.9). The stage of diagnosis was defined according to the Surveillance, Epidemiology, and End Results (SEER) summary stage classification. SEER stages were as follows: localized (limited to the organ of origin), regional (tumor extension beyond the limits of the organ of origin), distant (away from the primary tumor), and unknown.

Age‐standardized rates (ASRs) were calculated using the World Standard Population as the standard population.[14](#jgh14289-bib-0014){ref-type="ref"} Annual percent changes (APC) in the incidence rates were calculated based on a linear model using the following formula: (exp (*b*) − 1) × 100, where *b* is the slope of regression of the natural logarithm of ASR in a calendar year. The 95% confidence intervals (CIs) were obtained with standard error from the fit of the regression and the t‐distribution function.

Esophageal cancer survival {#jgh14289-sec-0009}
--------------------------

The survival duration for esophageal cancer patients was determined as the interval between the date of initial diagnosis and the date of death, date of loss to follow‐up, or the closing date of follow‐up (December 31, 2013). Survival rates were used from the data available for 1993. Time periods were chosen to allow comparison with those of an earlier study[13](#jgh14289-bib-0013){ref-type="ref"} and to estimate 5‐year survival rate for more recent data using complete approach.[15](#jgh14289-bib-0015){ref-type="ref"} Five‐year relative survival rates (RSRs) were calculated using the Ederer II method based on an algorithm written in SAS by Dickman with minor modifications. The 5‐year RSRs of years 1993--2013 by histological subtypes were calculated, and the changes in 5‐year RSRs from 1993--1995 to 2009--2013 were compared. The 1, 3, and 5‐year RSRs of patients diagnosed during 2006--2008 and 2009--2013 were calculated according to the SEER summary stages, which have been available since 2006. In addition, relative excess rates (RER) of patients diagnosed between 2009 and 2013 compared with patients diagnosed between 2006 and 2008 were estimated according to sex and SEER stage. All analyses were stratified by sex. Statistical analysis was performed using Stata/SE 10.0 for Windows (StataCorp LP, College Station, TX, USA) and SAS version 9.3 software (SAS Institute, Inc., Cary, NC, USA).

Results {#jgh14289-sec-0010}
=======

Time trends of incidence of esophageal cancer {#jgh14289-sec-0011}
---------------------------------------------

Overall, the number of diagnosed esophageal cancer cases has increased from 1864 in 1999 to 2382 cases in 2013 (Table [1](#jgh14289-tbl-0001){ref-type="table"}). Although the crude rate of esophageal cancer has increased, the ASRs decreased from 4.06 per 100 000 people in 1999 to 2.91 in 2013 with an APC of −2.2%. The same decreasing trends were observed for both men and women with APCs of −2.6% and −2.2%, respectively (Fig. [1](#jgh14289-fig-0001){ref-type="fig"}).

###### 

Crude incidence rates and age‐standardized incidence rates per 100 000 people[†](#jgh14289-note-0003){ref-type="fn"} for esophageal cancer and annual percent change by sex and histological subtypes, 1999--2013

  Histological group                                   Rates           Year   APC    *P*‐value                                                                                            
  ---------------------------------------------------- ------- ------ ------ ------ ----------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------- ----------- --
  Total                                                                                                                                                                                   
  Overall                                              Cases    1864   1769   1908     1946      1932   1983   2044   2046   2101   2201   2166   2233   2268   2354   2382               
  CR                                                   3.95     3.72   3.99   4.04     4.00      4.09   4.20   4.19   4.28   4.46   4.36   4.48   4.53   4.68   4.71                      
  ASR[†](#jgh14289-note-0003){ref-type="fn"}           4.06     3.69   3.88   3.77     3.62      3.56   3.54   3.39   3.32   3.34   3.14   3.13   3.03   3.02   2.91   −2.2   \< 0.0001   
  Squamous cell carcinoma                              Cases    1409   1310   1491     1541      1581   1625   1680   1714   1770   1909   1895   1985   2003   2102   2149               
  CR                                                   2.99     2.76   3.11   3.20     3.27      3.35   3.45   3.51   3.60   3.86   3.82   3.98   4.00   4.18   4.25                      
  ASR[†](#jgh14289-note-0003){ref-type="fn"}           3.08     2.76   3.05   3.02     2.98      2.94   2.92   2.87   2.82   2.91   2.76   2.79   2.69   2.71   2.63   −0.9   0.0003      
  Adenocarcinoma                                       Cases     64     59     64       60        64     76     78     76     86     87     78     67     76     69     75                
  CR                                                   0.14     0.12   0.13   0.12     0.13      0.16   0.16   0.16   0.18   0.18   0.16   0.13   0.15   0.14   0.15                      
  ASR[†](#jgh14289-note-0003){ref-type="fn"}           0.14     0.12   0.13   0.11     0.12      0.13   0.13   0.12   0.13   0.13   0.11   0.09   0.10   0.09   0.09   −2.7   0.0006      
  Other specified                                      Cases     50     69     53       58        52     52     70     62     62     69     58     65     82     67     56                
  CR                                                   0.11     0.15   0.11   0.12     0.11      0.11   0.14   0.13   0.13   0.14   0.12   0.13   0.16   0.13   0.11                      
  ASR[†](#jgh14289-note-0003){ref-type="fn"}           0.11     0.14   0.11   0.11     0.10      0.09   0.12   0.10   0.10   0.10   0.09   0.09   0.11   0.08   0.07   −2.6   0.0028      
  Unspecified                                          Cases    341    331    300       287      235    230    216    194    183    136    135    116    107    116     102               
  CR                                                   0.72     0.70   0.63   0.60     0.49      0.47   0.44   0.40   0.37   0.28   0.27   0.23   0.21   0.23   0.20                      
  ASR[†](#jgh14289-note-0003){ref-type="fn"}           0.72     0.67   0.59   0.53     0.42      0.40   0.36   0.30   0.27   0.20   0.18   0.15   0.13   0.13   0.12   −13.0  \< 0.0001   
  Men                                                                                                                                                                                     
  Overall                                              Cases    1708   1605   1733     1785      1738   1820   1885   1877   1899   2003   2003   2046   2073   2133   2186               
  CR                                                   7.21     6.73   7.21   7.39     7.17      7.48   7.72   7.66   7.71   8.09   8.05   8.19   8.26   8.47   8.65                      
  ASR[†](#jgh14289-note-0003){ref-type="fn"}           8.81     7.97   8.30   8.19     7.71      7.70   7.60   7.21   6.95   6.97   6.61   6.48   6.27   6.13   5.97   −2.6   \< 0.0001   
  Squamous cell carcinoma                              Cases    1335   1218   1399     1442      1468   1522   1590   1604   1632   1768   1781   1842   1853   1930   1995               
  CR                                                   5.64     5.10   5.82   5.97     6.06      6.26   6.51   6.55   6.63   7.14   7.16   7.37   7.39   7.66   7.89                      
  ASR[†](#jgh14289-note-0003){ref-type="fn"}           6.81     6.00   6.64   6.55     6.45      6.38   6.37   6.14   5.96   6.13   5.86   5.83   5.58   5.54   5.44   −1.4   \< 0.0001   
  Adenocarcinoma                                       Cases     57     49     46       50        51     67     66     63     66     74     69     53     64     55     69                
  CR                                                   0.24     0.21   0.19   0.21     0.21      0.28   0.27   0.26   0.27   0.30   0.28   0.21   0.26   0.22   0.27                      
  ASR[†](#jgh14289-note-0003){ref-type="fn"}           0.31     0.26   0.23   0.24     0.24      0.28   0.27   0.24   0.24   0.25   0.23   0.17   0.20   0.16   0.19   −3.1   0.0008      
  Other specified                                      Cases     43     60     46       53        44     47     63     54     51     59     47     57     69     56     42                
  CR                                                   0.18     0.25   0.19   0.22     0.18      0.19   0.26   0.22   0.21   0.24   0.19   0.23   0.28   0.22   0.17                      
  ASR[†](#jgh14289-note-0003){ref-type="fn"}           0.23     0.28   0.22   0.24     0.19      0.19   0.25   0.20   0.19   0.20   0.16   0.18   0.21   0.16   0.12   −3.6   0.0009      
  Unspecified                                          Cases    273    278    242       240      175    184    166    156    150    102    106     94     87     92     80                
  CR                                                   1.15     1.16   1.01   0.99     0.72      0.76   0.68   0.64   0.61   0.41   0.43   0.38   0.35   0.37   0.32                      
  ASR[†](#jgh14289-note-0003){ref-type="fn"}           1.46     1.42   1.22   1.16     0.82      0.85   0.71   0.63   0.56   0.39   0.36   0.30   0.28   0.27   0.23   −13.3  \< 0.0001   
  Women                                                                                                                                                                                   
  Overall                                              Cases    156    164    175       161      194    163    159    169    202    198    163    187    195    221     196               
  CR                                                   0.66     0.69   0.73   0.67     0.81      0.67   0.66   0.69   0.82   0.80   0.66   0.75   0.78   0.88   0.78                      
  ASR[†](#jgh14289-note-0003){ref-type="fn"}           0.56     0.55   0.58   0.51     0.59      0.47   0.43   0.47   0.52   0.50   0.38   0.44   0.43   0.48   0.41   −2.2   0.0014      
  Squamous cell carcinoma                              Cases     74     92     92       99       113    103     90    110    138    141    114    143    150    172     154   \`          
  CR                                                   0.32     0.39   0.39   0.41     0.47      0.43   0.37   0.45   0.56   0.57   0.46   0.57   0.60   0.68   0.61                      
  ASR[†](#jgh14289-note-0003){ref-type="fn"}           0.28     0.32   0.32   0.33     0.36      0.31   0.25   0.32   0.37   0.37   0.28   0.34   0.34   0.38   0.33    0.8   0.2396      
  Adenocarcinoma                                       Cases     7      10     18       10        13     9      12     13     20     13     9      14     12     14      6                
  CR                                                   0.03     0.04   0.08   0.04     0.05      0.04   0.05   0.05   0.08   0.05   0.04   0.06   0.05   0.06   0.02                      
  ASR[†](#jgh14289-note-0003){ref-type="fn"}           0.02     0.03   0.06   0.03     0.04      0.03   0.04   0.04   0.05   0.03   0.02   0.03   0.02   0.03   0.01   −4.2   0.0822      
  Other specified                                      Cases     7      9      7         5        8      5      7      8      11     10     11     8      13     11     14                
  CR                                                   0.03     0.04   0.03   0.02     0.03      0.02   0.03   0.03   0.04   0.04   0.04   0.03   0.05   0.04   0.06                      
  ASR[†](#jgh14289-note-0003){ref-type="fn"}           0.03     0.03   0.02   0.02     0.03      0.02   0.02   0.02   0.03   0.03   0.03   0.03   0.03   0.02   0.03    1.4   0.2393      
  Unspecified[†](#jgh14289-note-0003){ref-type="fn"}   Cases     68     53     58       47        60     46     50     38     33     34     29     22     20     24     22                
  CR                                                   0.29     0.22   0.24   0.20     0.25      0.19   0.21   0.16   0.13   0.14   0.12   0.09   0.08   0.10   0.09                      
  ASR[†](#jgh14289-note-0003){ref-type="fn"}           0.23     0.17   0.18   0.14     0.17      0.11   0.12   0.09   0.08   0.07   0.06   0.04   0.04   0.04   0.04   −12.3  \< 0.0001   

The World standard population was used as standard population.

Crude rates and ASRs are expressed per 100 000 people.

APC, annual percent change; ASR, age‐standardized rate; CR, crude rate.

![Age‐standardized incidence rates per 100 000 people for esophageal cancer by sex and histological subtypes, 1999--2013. (a) Total, (b) men, and (c) women. ![](JGH-33-1961-g003.jpg "image"), Overall; ![](JGH-33-1961-g004.jpg "image"), Squamous cell carcinoma; ![](JGH-33-1961-g005.jpg "image"), Adenocarcinoma; ![](JGH-33-1961-g006.jpg "image"), Other specified; ![](JGH-33-1961-g007.jpg "image"), Unspecified. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](JGH-33-1961-g001){#jgh14289-fig-0001}

Trends of esophageal cancer according to histological subtypes {#jgh14289-sec-0012}
--------------------------------------------------------------

More than 90% of all esophageal cancer cases were men. The most frequent histological subtype was squamous cell carcinoma, constituting 75.5% of all cases in 1999, gradually increasing to 90.2% in 2013 (Table [1](#jgh14289-tbl-0001){ref-type="table"}). However, after excluding unspecified histology cases, the proportion of squamous cell carcinomas was 92.5% in 1999 and 96% in 2013. The second most common histological subtype was adenocarcinoma, which constituted about 3% of all cases. In men, the ASRs of all histological types significantly decreased, whereas in women, the ASR of unspecified esophageal cancer decreased, but that of other esophageal cancers did not change between 1999 and 2013.

Trends of esophageal cancer according to Surveillance, Epidemiology, and End Results staging {#jgh14289-sec-0013}
--------------------------------------------------------------------------------------------

Table [2](#jgh14289-tbl-0002){ref-type="table"} shows the SEER summary stage distribution of esophageal cancer patients diagnosed during two periods: 2006--2009 and 2010--2013.

###### 

Incidence rates of esophageal cancer per 100 000 people according to age group and SEER stage, 2006--2013

  Year of diagnosis                2006--2009   2010--2013                            
  ------------------- ------------ ------------ ------------ ------ -------- -------- ------
  Age group           SEER stage                3.29                3.02              
  Total               Localized    2559         (30.1)       0.99   3045     (33.0)   1.00
  Regional            2781         (32.7)       1.09         3487   (37.8)   1.15     
  Distant             1514         (17.8)       0.59         1598   (17.3)   0.53     
  Unknown             1660         (19.5)       0.62         1107   (12.0)   0.34     
  0--64               Localized    963          (29.2)       0.45   1226     (33.0)   0.48
  Regional            1167         (35.4)       0.54         1511   (40.6)   0.59     
  Distant             669          (20.3)       0.31         690    (18.5)   0.27     
  Unknown             495          (15.0)       0.23         295    (7.9)    0.12     
  65--74              Localized    1103         (31.3)       8.54   1143     (33.9)   7.91
  Regional            1150         (32.6)       8.93         1276   (37.8)   8.89     
  Distant             616          (17.5)       4.79         579    (17.2)   4.05     
  Unknown             654          (18.6)       5.05         377    (11.2)   2.57     
  75+                 Localized    493          (29.1)       7.47   676      (31.6)   7.84
  Regional            464          (27.3)       6.96         700    (32.7)   7.96     
  Distant             229          (13.5)       3.44         329    (15.4)   3.77     
  Unknown             511          (30.1)       7.92         435    (20.3)   5.24     

ASR, age‐standardized rate; SEER, Surveillance, Epidemiology, and End Results.

The proportion of patients classified as unknown without staging were 19.5% in 2006--2009 but significantly decreased to 12.5% in 2010--2013. The proportion of patients diagnosed as localized stage increased from 30.1% in 2006--2009 to 33% in 2010--2013 and that of regional stage increased to 37.8% from 32.7%, respectively. The proportion of localized and regional cancer showed a higher tendency to increase than that of distant cancer in all age groups.

Trends of survival rates {#jgh14289-sec-0014}
------------------------

Overall RSR markedly improved during the observation period. Overall 5‐RSR was 12.8% between 1993 and 1995 but increased to 33.4% between 2009 and 2013 (Fig. [2](#jgh14289-fig-0002){ref-type="fig"}). Improvement in the 5‐year RSR was observed in all histological types, except in unspecified histology between 1993 and 2013 (Table [3](#jgh14289-tbl-0003){ref-type="table"}).

![Relative survival rates (%) of 1, 3, and 5 years of patients with esophageal cancer by period of diagnosis according to Surveillance, Epidemiology, and End Results stage. ![](JGH-33-1961-g008.jpg "image"), 1‐year; ![](JGH-33-1961-g009.jpg "image"), 3‐year; ![](JGH-33-1961-g010.jpg "image"), 5‐year. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](JGH-33-1961-g002){#jgh14289-fig-0002}

###### 

Five‐year relative survival (RSR, %) of patients with esophageal cancer by sex and histological subtypes, 1993--2013

  Year of diagnosis         1993--1995   1996--2000   2001--2005   2006--2010   2009--2013   1993--2013   Change[‡](#jgh14289-note-0008){ref-type="fn"} (%)                                       
  ------------------------- ------------ ------------ ------------ ------------ ------------ ------------ --------------------------------------------------- ------ ------ ------ ------- ------ ------
  Total                                                                                                                                                                                           
  Overall                   3377         12.8         7575         15.4         8756         21.2         9290                                                29.6   9665   33.4   34905   23.2   20.6
  Squamous cell carcinoma   2648         12.1         6145         15.8         7419         22.0         8249                                                30.9   8760   34.6   29833   24.3   22.5
  Adenocarcinoma            145          15.7         260          18.7         291          19.3         288                                                 26.0   268    29.6   1144    21.9   13.9
  Other specified           118          15.9         259          15.7         261          21.7         268                                                 24.7   277    28.0   1081    21.1   12.1
  Unspecified               466          14.7         911          11.9         785          14.4         485                                                 11.8   360    10.9   2847    12.9   −3.8
  Men                                                                                                                                                                                             
  Overall                   3119         11.9         6934         14.5         8036         20.5         8531                                                29.0   8861   33.1   32007   22.5   21.2
  Squamous cell carcinoma   2492         11.3         5714         15.0         6940         21.3         7661                                                30.2   8107   34.4   27750   23.6   23.1
  Adenocarcinoma            120          15.4         211          16.7         233          19.3         236                                                 27.3   230    29.4   939     21.9   14.0
  Other specified           109          15.2         231          14.8         231          20.9         231                                                 21.8   226    23.6   942     19.3   8.4
  Unspecified               398          13.4         778          10.0         632          11.6         403                                                 9.8    298    10.1   2376    11.0   −3.3
  Women                                                                                                                                                                                           
  Overall                   258          23.4         641          24.7         720          29.6         759                                                 36.8   804    36.1   2898    30.8   12.7
  Squamous cell carcinoma   156          24.8         431          25.0         479          32.1         588                                                 40.0   653    37.6   2083    33.4   12.8
  Adenocarcinoma            25           17.4         49           26.6         58           19.5         52                                                  20.0   38     29.5   205     21.5   12.1
  Other specified           9            24.6         28           23.6         30           28.4         37                                                  42.4   51     46.9   139     33.2   22.3
  Unspecified               68           22.2         133          23.2         153          26.0         82                                                  21.4   62     14.4   471     22.6   −7.8

Five‐year relative survival rate.

Change (%) in the 5‐year relative survival rates from 1993--1995 to 2009--2013.

RSR, relative survival rate.

Between 1993 and 1995, the 5‐RSRs were 12.1% for squamous cell carcinoma and 15.7% for adenocarcinoma, but between 2009 and 2013, the former was 34.6% and the latter was 29.6%. Therefore, the survival rate of squamous cell carcinoma increased more than that of adenocarcinoma. The overall survival rates of squamous cell carcinoma and adenocarcinoma were similar. When comparing the RSRs by gender and histological subtypes, there was a remarkable improvement in RSR of men with squamous cell carcinoma, which account for the majority of esophageal carcinoma patients.

Improvements in RSR were observed in localized and regional cancer patients diagnosed in 2009--2013 compared with patients diagnosed in 2006--2008. Particularly, the 5‐year survival rate of localized cancer was 49.5% during 2006--2008, and it improved significantly to 58.5% between 2009 and 2013 (Fig. [2](#jgh14289-fig-0002){ref-type="fig"}). RER was 0.72 (95% CI 0.65--0.80) in localized cancer and 0.88 (95% CI, 0.82--0.95) in regional cancer among patients diagnosed in 2009--2013, compared with those in 2006--2008. RER was most reduced in men with localized stage (Table [4](#jgh14289-tbl-0004){ref-type="table"}).

###### 

Estimated relative excess risks of esophageal cancer in Korea

  SEER stage   Both   Men          Women                                                           
  ------------ ------ ------------ ----------- ------ ------------ ----------- ------ ------------ --------
  Local                                                                                            
  2006--2008   1.00   Reference    \< 0.0001   1.00   Reference    \< 0.0001   1.00   Reference    0.6238
  2009--2013   0.72   0.65--0.80               0.69   0.62--0.77               1.08   0.79--1.49   
  Regional                                                                                         
  2006--2008   1.00   Reference    0.0005      1.00   Reference    0.0007      1.00   Reference    0.4473
  2009--2013   0.88   0.82--0.95               0.88   0.82--0.95               0.90   0.70--1.17   
  Distant                                                                                          
  2006--2008   1.00   Reference    0.2396      1.00   Reference    0.1800      1.00   Reference    0.6722
  2009--2013   1.05   0.97--1.15               1.06   0.97--1.16               0.93   0.67--1.29   
  Unknown                                                                                          
  2006--2008   1.00   Reference    0.4089      1.00   Reference    0.3342      1.00   Reference    0.7582
  2009--2013   0.96   0.86--1.06               0.95   0.85--1.06               1.06   0.75--1.49   

CI, confidence interval; LR, likelihood risk; RER, relative excess risks; SEER, Surveillance, Epidemiology, and End Results.

Discussion {#jgh14289-sec-0015}
==========

Esophageal cancer incidence has decreased in both men and women. More than 90% of esophageal cancers are squamous cell carcinomas, and the incidences of both squamous cell carcinoma and adenocarcinoma have decreased significantly. Similar to our results, squamous cell carcinoma is the most common type of esophageal cancer in Japan and China[5](#jgh14289-bib-0005){ref-type="ref"}; however, in the USA and British Columbia in Canada, adenocarcinoma is the most common type in men, and squamous cell carcinoma is the most common type in women.[8](#jgh14289-bib-0008){ref-type="ref"}, [9](#jgh14289-bib-0009){ref-type="ref"} A decrease in incidence as well as mortality have been observed in both developing and developed countries.[16](#jgh14289-bib-0016){ref-type="ref"} In contrast, the prevalence of adenocarcinoma continuously increased between 1975 and 2009 in the USA, although the increasing trend has slowed since 1998.[7](#jgh14289-bib-0007){ref-type="ref"}

Risk factors for esophageal cancer differ by histological subtype. As established risk factor for esophageal adenocarcinoma is bodyfat and that for squamous cell carcinoma is alcohol consumption according to a systematic review by World Cancer Research Fund/American Institute for Cancer Research.[17](#jgh14289-bib-0017){ref-type="ref"} In addition, cigarette smoking and insufficient intake of vegetable and fruits are more strongly related with the risk of squamous cell carcinomas.[18](#jgh14289-bib-0018){ref-type="ref"}, [19](#jgh14289-bib-0019){ref-type="ref"} Prevalence of cigarette smoking, especially among men, has dramatically decreased during the last few decades in Korea.[20](#jgh14289-bib-0020){ref-type="ref"} However, the prevalence of high‐risk alcohol consumers has slightly increased in both men (19.9% to 20.8%) and women (3.4% to 5.8%) between 2005 and 2015,[21](#jgh14289-bib-0021){ref-type="ref"} and prevalence of insufficient consumption of non‐salted vegetables and fruits did not change significantly between 1998 and 2012.[22](#jgh14289-bib-0022){ref-type="ref"} In addition, the prevalence of obesity gradually increased from 25.7% in 1998 to 35.1% in 2005 and 37.9% in 2013--2014 in men, when obesity was defined as having a body mass index of 25 kg/m^2^ or higher; however, the prevalence of obesity in women decreased during the same period.[23](#jgh14289-bib-0023){ref-type="ref"} The prevalence of GERD tends to increase,[24](#jgh14289-bib-0024){ref-type="ref"} whereas Barrett\'s esophagus, which is a precancerous lesion of esophageal adenocarcinoma, is still very rare in Korea.[25](#jgh14289-bib-0025){ref-type="ref"} In addition to dynamic changes in risk factors in both elevating the risk (GERDs, high‐risk alcohol consumption, and obesity in men) and lowering the risk (decrease in smoking prevalence), it is possible that gastric cancer occurred in cardia was diagnosed as adenocarcinoma occurred in the lower esophagus until AJCC 8 edition clearly defined esophago‐gastric junction cancer.[26](#jgh14289-bib-0026){ref-type="ref"} Stomach cancer in Korea including cardia, body, and antrum is decreasing[10](#jgh14289-bib-0010){ref-type="ref"}, therefore, we cannot completely rule out the possibility of potential misclassification of the cancer site.

An increase in the survival of esophageal cancer patients may be explained by introduction of the NCSP. According to the Korean National Cancer Screening Survey, the lifetime usage of upper endoscopy for stomach cancer screening has gradually increased from 32.4% in 2004 to 64.4% in 2013,[27](#jgh14289-bib-0027){ref-type="ref"} and it may have helped in the early detection and treatment of precancerous lesions as well as related conditions such as GERD.

The relative survival of esophageal cancer has improved recently in localized and regional stages, but not in the distant stage. The overall survival in Korea is higher compared with reports from the USA (20.1% for 2005--2011) and Canada (15% for 2006--2008) and lower than that of Japan (33.7% for 2003--2005). When compared with US SEER data for 1998--2009, our results showed a higher 5‐year relative survival in all SEER stages. RER showed an improvement of 31% in male patients with localized stage and 18% in male patients with regional stage, indicating that the highest increase in RSR was in men with early‐stage esophageal cancer. Aggressive surgical treatment and endoscopic submucosal dissection (ESD) have improved the survival rate of early‐stage esophageal cancer. ESD has the advantage of permitting en bloc and complete histological resection of early esophageal cancer. Recent studies have shown that ESD of superficial esophageal cancer yielded a comparable survival rate with that of surgery and improved the patients\' quality of life without complications accompanying the surgery.[28](#jgh14289-bib-0028){ref-type="ref"}, [29](#jgh14289-bib-0029){ref-type="ref"}

The five‐year RSRs were higher among women than men in all histological types. Based on a previous study from the KCCR, women showed a higher survival rate than men even after adjustments for years of follow‐up, age, SEER summary stage, and casemix, and the differences in survival rates were statistically significant among the age group of 50--74 years old.[30](#jgh14289-bib-0030){ref-type="ref"} Consistent with our results, female esophageal cancer patients showed better survival than male patients in US SEER data,[31](#jgh14289-bib-0031){ref-type="ref"} the British Columbia Cancer Registry of Canada,[9](#jgh14289-bib-0009){ref-type="ref"} Europe,[32](#jgh14289-bib-0032){ref-type="ref"} and China.[33](#jgh14289-bib-0033){ref-type="ref"} In previous analyses, women were more likely to be presented with localized stage than men.[30](#jgh14289-bib-0030){ref-type="ref"} Although the stage and casemix were considered in the analysis, we still cannot exclude the possibility of differential casemix between men and women even within the same SEER stage groups.

The strength of the current study is it being the first population‐based approach by using cancer registry data with high quality and completeness in Korea. The limitation, however, includes relatively high proportions of unspecified subsites and unknown SEER stages especially in the early period of the registry, which makes interpretation by time difficult. The proportion of unspecified histology has decreased from 18% in 1999 to 4% in 2013; therefore, an increase in the proportion of squamous cell carcinoma can be partly explained by improvements in reporting of morphology information. When esophageal cancers were classified by anatomical subsites, around half of all patients were coded as "overlapping or not otherwise specified (NOS)" during 1999 and 2003, and the proportion of "overlapping or NOS" cancers gradually decreased until 2013 ([Table S2](#jgh14289-supitem-0001){ref-type="supplementary-material"}). Esophageal cancer occurred most frequently in the mid‐esophagus, and the upper and lower esophagus showed a similar incidence. Although significant trends in incidence of subtypes were observed, it is difficult to interpret whether it was a true change because of the substantially high proportion of NOS tumors. Second, because of limited treatment information, we could not analyze the influence of treatment approaches on changes in the survival rates, which is an important prognostic factor. Lastly, the effect of lead‐time bias on improvement of esophageal cancer patients, which could be introduced after the application of NCSP, could not be evaluated.

In conclusion, this study indicates a continuous decrease in the incidence of esophageal cancer and an increase in its survival rate. Improvement in survival may be affected by the relative increase in early detection of localized cancer. Esophageal cancer is difficult to detect early, and surgery is enforced restrictively despite definitive treatment options. Further studies on improvements in the survival rate of esophageal carcinoma in relation to early detection and subsequent shifts in the treatment modality by time should be pursued.
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**Table S1.** Data quality indices for esophageal cancer, the Korea Central Cancer Registry, 1999--2013.

**Table S2.** Age‐standardized esophageal cancer incidence rates per 100 000 and annual percent changes (APC) by subsites, 1999--2013.
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Click here for additional data file.
